Proteotoxic stress and circulating cell stress proteins in the cardiovascular diseases
نویسندگان
چکیده
منابع مشابه
Stressing the obvious? Cell stress and cell stress proteins in cardiovascular disease.
It is only some forty years since the discovery of the heat shock or cell stress response and just over twenty years since the heat shock/cell stress response was linked to protein misfolding. The plethora of intracellular proteins which promote correct protein folding in the cell, variously termed molecular chaperones, heat shock proteins, or cell stress proteins, have only been identified in ...
متن کاملOxidative Stress and Cardiovascular Diseases
Reactive oxygen species (ROS) are reactive oxygen metabolites resulting from one-electron reduction of oxygen under the influence of a variety of enzymes. In aerobic organisms, they are produced as a byproduct of many cellular metabolic pathways and participate in some processes necessary for the normal life and functioning of the cells, but also in a large number of pathological processes. Oxi...
متن کاملPsychosocial stress and cardiovascular diseases.
Fifty five years after the first finding relating mood disturbances and cardiovascular diseases, there is still debate on the formation of a cogent conception embracing all the fragments of insight within the various aspects relating psychosocial stress to cardiovascular diseases. The clinical comorbidity is empirically evident, but there are ambiguous research results limiting the value of the...
متن کاملAneuploidy and proteotoxic stress in cancer
Although nearly ubiquitous in cancer, aneuploidy exerts detrimental effects on human cells. We recently demonstrated that aneuploid human cells exhibit impaired heat shock factor protein 1 (HSF1) and HSP90 function, suggesting a functional link between two recurring features of cancer cells: aneuploidy and proteotoxic stress. Further, our findings implicate HSF1 as a key factor in mitigating th...
متن کاملProteotoxic stress targeted therapy (PSTT)
About a decade ago a multiple myeloma patient demonstrated a complete response to a proteasome inhibitor Bortezomib. This case generated a lot of hopes, and after successful clinical trials Bortezomib was approved by FDA and became the drug of choice for this disease. A high sensitivity of multiple myeloma to proteasome inhibition is probably related to extensive production immunoglobulins by t...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cell Stress and Chaperones
سال: 2012
ISSN: 1355-8145,1466-1268
DOI: 10.1007/s12192-011-0318-y